Drug intelligence / Profile preview

Fertivista Forte

Development stage: Unknown
Lead developer: Gynavista
Modality: Small Molecules
Administration: Oral

Overview

**Fertivista Forte** is an oral antioxidant fertility-support formulation marketed by Gynavista. It contains astaxanthin 10% 16 mg and reduced coenzyme Q10 200 mg. The product is positioned for female fertility support, including ovulation, egg quality, ovarian function, oxidative-stress reduction, and reproductive wellness. Astaxanthin provides antioxidant activity, while reduced coenzyme Q10 supports mitochondrial energy metabolism; no specific molecular drug target is disclosed by the product sources.

Brand names: Fertivista Forte

Beyond the preview

Go deeper on Fertivista Forte.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fertivista Forte.

Explore the full profile